Immatics

The page details Immatics’ ongoing clinical trials.

Explore Immatics’ pipeline, including product candidates, treatment modalities and combination approaches in development.

Understand PRAME, the technology behind Immatics’ immunotherapies in development and why precision targeting matters in cancer treatment.

The page lists Immatics’ scientific publications and conference presentations from recent years.

Immatics describes how its culture fosters growth, collaboration, and impact for cancer patients.

Explore various roles at Immatics in Munich and Tuebingen and join a trans-Atlantic team.

Immatics lists job opportunities in Houston and highlights its transatlantic team structure.

Immatics introduces its Board of Directors and their combined medical, scientific, academic, and business expertise.

Meet Immatics’ management team, an interdisciplinary group of medical, scientific and business leaders across Houston, Texas and Germany.

Immatics’ Scientific Advisory Board brings expertise in immunooncology, adoptive cell therapies, clinical oncology and cancer biology.

Immatics is the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers.

The page offers contact details for inquiries about Immatics’ research, clinical trials, or company.

Immatics specializes in precision targeting of PRAME and highlights its science, clinical pipeline, and trials.

Immatics outlines its privacy policy, data protection measures, user rights, and cookie usage.

Immatics explains its data protection practices, user rights, and cookie usage.

Treatment through an Expanded Access Program (EAP). Get more information about the criteria and the process.

Immatics provides legally required contact details, representatives, and registration information.

Immatics presents updated clinical trial data for **IMA402**, a PRAME-targeting bispecific therapy, and **IMA203CD8**, a PRAME-directed cell therapy, in advanced solid tumors. The findings come from an ongoing **Phase 1b study** for IMA402 and a **Phase 1 study** for IMA203CD8, both showcased at the **2026 ESMO Annual Meeting**. The company highlights early clinical activity across multiple precision oncology programs targeting the PRAME antigen.

Oct 2026Immatics N.V.News article

Immatics raises **$150 million** through an underwritten offering of **12.9 million shares** at **$8.69 per share**, alongside pre-funded warrants for an additional **4.3 million shares** at **$8.689**. The company, specializing in **precision targeting of PRAME** across **cell therapies and bispecifics**, secures capital to advance its **clinical-stage programs**.

Aug 2026Immatics N.V.News article

Immatics reports second-quarter 2026 financial results and a business update, highlighting its focus on precision targeting of PRAME across clinical-stage programs in cell therapies and bispecifics. The company, listed on NASDAQ as IMTX, provides an overview of its ongoing developments in immuno-oncology.

Aug 2026Immatics N.V.News article

Immatics presents updated Phase 1b trial data on **anzu-cel (IMA203)**, a PRAME-targeting TCR T-cell therapy, showing clinical activity in heavily pretreated advanced melanoma patients. The findings are shared in an oral presentation at the 2026 ASCO Annual Meeting, highlighting response dynamics from ongoing evaluations. The company specializes in precision targeting of PRAME across cell therapies and bispecific programs.

Jun 2026Immatics N.V.News article